150 related articles for article (PubMed ID: 30326853)
1. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Kim MK; Yee J; Cho YS; Jang HW; Han JM; Gwak HS
BMC Cancer; 2018 Oct; 18(1):988. PubMed ID: 30326853
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study.
Han JM; Han HW; Yee J; Kim MK; Moon JY; Cho S; Jung D; Cho YS; Seo I; Kim JY; Gwak HS
Eur J Clin Pharmacol; 2020 Aug; 76(8):1183-1191. PubMed ID: 32444938
[TBL] [Abstract][Full Text] [Related]
3. Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity.
Moon JY; Han JM; Seo I; Gwak HS
Breast Cancer Res Treat; 2019 Nov; 178(1):239-244. PubMed ID: 31372791
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity.
Park YH; Cho S; Yee J; Kim JY; Rhie SJ; Gwak HS
Anticancer Drugs; 2018 Jun; 29(5):471-476. PubMed ID: 29557814
[TBL] [Abstract][Full Text] [Related]
5. Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.
Cho S; Yee J; Kim JY; Jeong Rhie S; Gwak HS
J Clin Pharmacol; 2018 Feb; 58(2):263-268. PubMed ID: 28981161
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients.
Jung D; Han JM; Yee J; Kim JY; Gwak HS
Med Oncol; 2018 Oct; 35(12):154. PubMed ID: 30367285
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
[TBL] [Abstract][Full Text] [Related]
9. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
11. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
12. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
13. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
[TBL] [Abstract][Full Text] [Related]
14. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
[TBL] [Abstract][Full Text] [Related]
18. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interactions and Disease Status Are Associated With Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai.
Li J; Chen B; Xi WQ; Jia W; Zhang WX; Bian XL
J Clin Pharmacol; 2022 Sep; 62(9):1160-1169. PubMed ID: 35396702
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
